Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reverse Genetics Is Best Path To Cell Culture Vaccines – FDA Committee

Executive Summary

Reverse genetics holds the greatest promise for developing cell culture-based vaccines, FDA's Vaccines & Related Biological Products Advisory Committee said Feb. 19

You may also be interested in...



Influenza B strain confirmed

FDA's Vaccines & Related Biological Products Advisory Committee unanimously confirms its selection of Yamagata lineage Shanghai/361/2002-like influenza B strain for 2004-2005 vaccine by teleconference March 17. In February, the committee said the two influenza A strains in next season's flu vaccine should be a New Caledonia/20/1999 (H1N1)-like strain and a Fujian/411/2002 (H3N2)-like strain, but delayed a final decision on influenza B (1"The Pink Sheet" Feb. 23, 2004, p. 32)...

Influenza B strain confirmed

FDA's Vaccines & Related Biological Products Advisory Committee unanimously confirms its selection of Yamagata lineage Shanghai/361/2002-like influenza B strain for 2004-2005 vaccine by teleconference March 17. In February, the committee said the two influenza A strains in next season's flu vaccine should be a New Caledonia/20/1999 (H1N1)-like strain and a Fujian/411/2002 (H3N2)-like strain, but delayed a final decision on influenza B (1"The Pink Sheet" Feb. 23, 2004, p. 32)...

Influenza vaccine formulation

FDA's Vaccines & Related Biological Products Advisory Committee will meet March 17 by teleconference to finalize the influenza vaccine formulation for the 2004-2005 flu season. At a Feb. 18-19 meeting, the committee recommended switching one of the two influenza A strains, and switching a Victoria lineage strain to Yamagata for the influenza B component (1"The Pink Sheet" Feb. 23, 2004, p. 32). A speakerphone will be available to the public in FDA's Building 29 B Conference Room C from 1 p.m. to 5 p.m...

UsernamePublicRestriction

Register

MT142539

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel